Selected research
Industry Research
Vaccine (Include COVID-19) Industry Research Report 2026
Market perspective
The global Vaccine (Include COVID-19) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Vaccine (Include COVID-19) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Vaccine (Include COVID-19) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Vaccine (Include COVID-19) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Vaccine (Include COVID-19) include Sanofi, Merck, Pfizer, GSK, AstraZeneca, Zhejiang Pukang, Walvax Biotechnology, Viatris and Sinovac, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Vaccine (Include COVID-19) market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Vaccine (Include COVID-19).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vaccine (Include COVID-19) Market by Company
Sanofi
Merck
Pfizer
GSK
AstraZeneca
Zhejiang Pukang
Walvax Biotechnology
Viatris
Sinovac
Sinovac
Serum Institute
Panacea Biotec Ltd
LG Life Sciences
KM Biologics
Hualan Bio
Halfkin Bio-Pharmaceuticals
CSL
Changchun Institute of Biological
Bio-Med
Bharat Biotech
Vaccine (Include COVID-19) Segment by Type
Inactivated Vaccine
Attenuated Vaccine
mRNA
Other
Vaccine (Include COVID-19) Segment by Application
Public
Private
Vaccine (Include COVID-19) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine (Include COVID-19) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaccine (Include COVID-19) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine (Include COVID-19).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Vaccine (Include COVID-19) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Inactivated Vaccine
- Attenuated Vaccine
- mRNA
- Other
Applications
- Public
- Private
Companies covered
- Sanofi
- Merck
- Pfizer
- GSK
- AstraZeneca
- Zhejiang Pukang
- Walvax Biotechnology
- Viatris
- Sinovac
- Sinovac
- Serum Institute
- Panacea Biotec Ltd
- LG Life Sciences
- KM Biologics
- Hualan Bio
- Halfkin Bio-Pharmaceuticals
- CSL
- Changchun Institute of Biological
- Bio-Med
- Bharat Biotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Vaccine (Include COVID-19) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Inactivated Vaccine
- 2.2.3 Attenuated Vaccine
- 2.2.4 mRNA
- 2.2.5 Other
- 2.3 Vaccine (Include COVID-19) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Public
- 2.3.3 Private
- 2.4 Assumptions and Limitations
3 Vaccine (Include COVID-19) Breakdown Data by Type
- 3.1 Global Vaccine (Include COVID-19) Historic Market Size by Type (2021-2026)
- 3.2 Global Vaccine (Include COVID-19) Forecasted Market Size by Type (2027-2032)
4 Vaccine (Include COVID-19) Breakdown Data by Application
- 4.1 Global Vaccine (Include COVID-19) Historic Market Size by Application (2021-2026)
- 4.2 Global Vaccine (Include COVID-19) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Vaccine (Include COVID-19) Market Perspective (2021-2032)
- 5.2 Global Vaccine (Include COVID-19) Growth Trends by Region
- 5.2.1 Global Vaccine (Include COVID-19) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Vaccine (Include COVID-19) Historic Market Size by Region (2021-2026)
- 5.2.3 Vaccine (Include COVID-19) Forecasted Market Size by Region (2027-2032)
- 5.3 Vaccine (Include COVID-19) Market Dynamics
- 5.3.1 Vaccine (Include COVID-19) Industry Trends
- 5.3.2 Vaccine (Include COVID-19) Market Drivers
- 5.3.3 Vaccine (Include COVID-19) Market Challenges
- 5.3.4 Vaccine (Include COVID-19) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Vaccine (Include COVID-19) Players by Revenue
- 6.1.1 Global Top Vaccine (Include COVID-19) Players by Revenue (2021-2026)
- 6.1.2 Global Vaccine (Include COVID-19) Revenue Market Share by Players (2021-2026)
- 6.2 Global Vaccine (Include COVID-19) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Vaccine (Include COVID-19) Head Office and Area Served
- 6.4 Global Vaccine (Include COVID-19) Players, Product Type & Application
- 6.5 Global Vaccine (Include COVID-19) Manufacturers Established Date
- 6.6 Global Vaccine (Include COVID-19) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Vaccine (Include COVID-19) Market Size (2021-2032)
- 7.2 North America Vaccine (Include COVID-19) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Vaccine (Include COVID-19) Market Size by Country (2021-2026)
- 7.4 North America Vaccine (Include COVID-19) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Vaccine (Include COVID-19) Market Size (2021-2032)
- 8.2 Europe Vaccine (Include COVID-19) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Vaccine (Include COVID-19) Market Size by Country (2021-2026)
- 8.4 Europe Vaccine (Include COVID-19) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Vaccine (Include COVID-19) Market Size (2021-2032)
- 9.2 Asia-Pacific Vaccine (Include COVID-19) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Vaccine (Include COVID-19) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Vaccine (Include COVID-19) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Vaccine (Include COVID-19) Market Size (2021-2032)
- 10.2 South America Vaccine (Include COVID-19) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Vaccine (Include COVID-19) Market Size by Country (2021-2026)
- 10.4 South America Vaccine (Include COVID-19) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Vaccine (Include COVID-19) Market Size (2021-2032)
- 11.2 Middle East & Africa Vaccine (Include COVID-19) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Vaccine (Include COVID-19) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Vaccine (Include COVID-19) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.1.4 Sanofi Vaccine (Include COVID-19) Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Merck
- 12.2.1 Merck Company Information
- 12.2.2 Merck Business Overview
- 12.2.3 Merck Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.2.4 Merck Vaccine (Include COVID-19) Product Portfolio
- 12.2.5 Merck Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.3.4 Pfizer Vaccine (Include COVID-19) Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 GSK
- 12.4.1 GSK Company Information
- 12.4.2 GSK Business Overview
- 12.4.3 GSK Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.4.4 GSK Vaccine (Include COVID-19) Product Portfolio
- 12.4.5 GSK Recent Developments
- 12.5 AstraZeneca
- 12.5.1 AstraZeneca Company Information
- 12.5.2 AstraZeneca Business Overview
- 12.5.3 AstraZeneca Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.5.4 AstraZeneca Vaccine (Include COVID-19) Product Portfolio
- 12.5.5 AstraZeneca Recent Developments
- 12.6 Zhejiang Pukang
- 12.6.1 Zhejiang Pukang Company Information
- 12.6.2 Zhejiang Pukang Business Overview
- 12.6.3 Zhejiang Pukang Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.6.4 Zhejiang Pukang Vaccine (Include COVID-19) Product Portfolio
- 12.6.5 Zhejiang Pukang Recent Developments
- 12.7 Walvax Biotechnology
- 12.7.1 Walvax Biotechnology Company Information
- 12.7.2 Walvax Biotechnology Business Overview
- 12.7.3 Walvax Biotechnology Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.7.4 Walvax Biotechnology Vaccine (Include COVID-19) Product Portfolio
- 12.7.5 Walvax Biotechnology Recent Developments
- 12.8 Viatris
- 12.8.1 Viatris Company Information
- 12.8.2 Viatris Business Overview
- 12.8.3 Viatris Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.8.4 Viatris Vaccine (Include COVID-19) Product Portfolio
- 12.8.5 Viatris Recent Developments
- 12.9 Sinovac
- 12.9.1 Sinovac Company Information
- 12.9.2 Sinovac Business Overview
- 12.9.3 Sinovac Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.9.4 Sinovac Vaccine (Include COVID-19) Product Portfolio
- 12.9.5 Sinovac Recent Developments
- 12.10 Sinovac
- 12.10.1 Sinovac Company Information
- 12.10.2 Sinovac Business Overview
- 12.10.3 Sinovac Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.10.4 Sinovac Vaccine (Include COVID-19) Product Portfolio
- 12.10.5 Sinovac Recent Developments
- 12.11 Serum Institute
- 12.11.1 Serum Institute Company Information
- 12.11.2 Serum Institute Business Overview
- 12.11.3 Serum Institute Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.11.4 Serum Institute Vaccine (Include COVID-19) Product Portfolio
- 12.11.5 Serum Institute Recent Developments
- 12.12 Panacea Biotec Ltd
- 12.12.1 Panacea Biotec Ltd Company Information
- 12.12.2 Panacea Biotec Ltd Business Overview
- 12.12.3 Panacea Biotec Ltd Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.12.4 Panacea Biotec Ltd Vaccine (Include COVID-19) Product Portfolio
- 12.12.5 Panacea Biotec Ltd Recent Developments
- 12.13 LG Life Sciences
- 12.13.1 LG Life Sciences Company Information
- 12.13.2 LG Life Sciences Business Overview
- 12.13.3 LG Life Sciences Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.13.4 LG Life Sciences Vaccine (Include COVID-19) Product Portfolio
- 12.13.5 LG Life Sciences Recent Developments
- 12.14 KM Biologics
- 12.14.1 KM Biologics Company Information
- 12.14.2 KM Biologics Business Overview
- 12.14.3 KM Biologics Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.14.4 KM Biologics Vaccine (Include COVID-19) Product Portfolio
- 12.14.5 KM Biologics Recent Developments
- 12.15 Hualan Bio
- 12.15.1 Hualan Bio Company Information
- 12.15.2 Hualan Bio Business Overview
- 12.15.3 Hualan Bio Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.15.4 Hualan Bio Vaccine (Include COVID-19) Product Portfolio
- 12.15.5 Hualan Bio Recent Developments
- 12.16 Halfkin Bio-Pharmaceuticals
- 12.16.1 Halfkin Bio-Pharmaceuticals Company Information
- 12.16.2 Halfkin Bio-Pharmaceuticals Business Overview
- 12.16.3 Halfkin Bio-Pharmaceuticals Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.16.4 Halfkin Bio-Pharmaceuticals Vaccine (Include COVID-19) Product Portfolio
- 12.16.5 Halfkin Bio-Pharmaceuticals Recent Developments
- 12.17 CSL
- 12.17.1 CSL Company Information
- 12.17.2 CSL Business Overview
- 12.17.3 CSL Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.17.4 CSL Vaccine (Include COVID-19) Product Portfolio
- 12.17.5 CSL Recent Developments
- 12.18 Changchun Institute of Biological
- 12.18.1 Changchun Institute of Biological Company Information
- 12.18.2 Changchun Institute of Biological Business Overview
- 12.18.3 Changchun Institute of Biological Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.18.4 Changchun Institute of Biological Vaccine (Include COVID-19) Product Portfolio
- 12.18.5 Changchun Institute of Biological Recent Developments
- 12.19 Bio-Med
- 12.19.1 Bio-Med Company Information
- 12.19.2 Bio-Med Business Overview
- 12.19.3 Bio-Med Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.19.4 Bio-Med Vaccine (Include COVID-19) Product Portfolio
- 12.19.5 Bio-Med Recent Developments
- 12.20 Bharat Biotech
- 12.20.1 Bharat Biotech Company Information
- 12.20.2 Bharat Biotech Business Overview
- 12.20.3 Bharat Biotech Revenue in Vaccine (Include COVID-19) Business (2021-2026)
- 12.20.4 Bharat Biotech Vaccine (Include COVID-19) Product Portfolio
- 12.20.5 Bharat Biotech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst